PHA Classroom: e-Learning. Anytime. Anyplace.

>> Back to Recordings
 
Session Recording from PHA's 2010 9th International PH Conference

Congenital Heart Disease & PH

June 26, 2010 

How does congenital heart disease lead to PH? What are the options for patients who have developed PH in conjunction with congenital heart disease? This session will focus on the various forms of congenital heart disease that might lead to PH and look at the options available to patients. We will review the known medical therapies for PH with congenital heart disease, and discuss when patients should consider PH medicines.

The below recording will begin automatically. To view the controls, move your mouse anywhere over the video then move to the control interface at the bottom of the video.

 

 

Presenter Information

-Jeffrey Feinstein, MD, Stanford University, Stanford, Calif. (chair)
-Robyn Barst, MD, Columbia University, New York, N.Y.
-Delphine Yung, MD, Seattle Children’s Hospital, Seattle, Wash.
 

DIAMOND
SUPPORTER

PLATINUM
SUPPORTER

GOLD
SUPPORTER

SILVER
SUPPORTER

Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. United Therapeutics Corporation Bayer HealthCare
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.

 

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2014 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.